Michael Hallek, MD¹, Guenter Fingerle-Rowson, MD, PhD^1*, Anna- Maria Fink, MD^1*, Raymonde Busch^2*, Jiri Mayer, MD^3*, Manfred Hensel, MD^4*, Georg Hopfinger, MD^5*, Georg Hess, MD^6*, Ulrich von Gruenhagen, MD^7*, Manuela A. Bergmann, MD⁸, John Catalano, MD⁹, Pier Luigi Zinzani, MD^10*, Federico Caligaris Cappio, MD^11*, John Francis Seymour, MBBS¹², Alain Berrebi, MD^13*, Ulrich Jaeger, MD¹⁴, Bruno Cazin, MD^15*, Marek Trneny, MD, PhD¹⁶, Anne Westermann^1*, Clemens-Martin Wendtner, MD¹, Barbara F. Eichhorst, MD¹, Peter Staib, MD^17*, Sebastian Boettcher, MD^18*, Matthias Ritgen, MD^19*, Stephan Stilgenbauer, MD²⁰, Myriam Mendila, MD^21*, Michael Kneba, MD, PhD¹⁹, Hartmut Döhner, MD^20* and Kirsten Fischer, MD^1*

¹Department I of Internal Medicine, University of Cologne, Cologne, Germany
²Technical University, Institute for Medical Statistic and Epidemiology, Munich, Germany
³Hematology/Oncology, Masaryk University Hospital, Brno, Czech Republic
⁴University of Heidelberg, Mannheim, Germany
⁵Department of Medicine III, Hanusch Hospital, Vienna, Austria
⁶Johannes Gutenberg-Universität, Mainz, Germany
⁷Praxis für Hämatologie/Onkologie, Cottbus, Germany
⁸Hem./Onc., Univ. Hosp. Munich, Muenchen, Germany
⁹Dorevitch Pathology Laboratory, Frankston Hospital, Frankston, VIC, Australia
¹⁰Department of Hematology/Oncology, University of Bologna, Bologna, Italy
¹¹Ospedale San Raffaele, Milano, Italy
¹²Peter MacCallum Cancer Institute, Richmond, Australia
¹³Kaplan Medical Center, Rehovot, Israel
¹⁴Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
¹⁵Service des Maladies du Sang, Hopital Claude Huriez, Lille, France
¹⁶First Dept. of Medicine, Charles Univ. General Hosp., Prague, Czech Republic
¹⁷Klinik für Hämatologie und Onkologie, St.-Antonius Hospital, Eschweiler, Germany
¹⁸Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany
¹⁹Department of Internal Medicine II, University Hospital, Kiel, Germany
²⁰Internal Medicine III, University of Ulm, Ulm, Germany
²¹Pharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Sebastian Boettcher, MD^1*, Kirsten Fischer, MD^2*, Stephan Stilgenbauer, MD, PhD³, Raymonde Busch^4*, Günter Fingerle-Rowson, MD, PhD^2*, Anna-Maria Fink, MD^2*, Hartmut Döhner, MD, PhD^3*, Michael Hallek, MD, PhD^2*, Michael Kneba, MD, PhD¹, Matthias Ritgen, MD^1* and on Behalf Of GCLLSG^5*

¹Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany
²Department of Internal Medicine I, University of Cologne, Cologne, Germany
³Internal Medicine III, University of Ulm, Ulm, Germany
⁴Technical University, Institute for Medical Statistic and Epidemiology, Munich, Germany
⁵the German CLL Study Group (GCLLSG)

Craig Reynolds, MD¹, Nicholas Di Bella, MD², Roger M. Lyons, MD³, William J Hyman, MD^4*, Gary L. Lee, MD^5*, Donald A Richards, MD, PhD^4*, Gerald J. Robbins, MD^6*, Mark Vellek, MD⁷, Kristi A Boehm, MS^8*, Feng Zhan, PhD^8* and Lina Asmar, PhD^8*

¹US Oncology Research, Inc., Houston, TX and Ocala Oncology Center, Ocala, FL
²US Oncology Research, Inc., Houston, TX and Rocky Mountain Cancer Centers, Aurora, CO
³US Oncology Research, Inc., Houston, TX and Cancer Care Centers of South Texas, San Antonio, TX
⁴US Oncology Research, Inc., Houston, TX and Tyler Cancer Center, Tyler, TX
⁵US Oncology Research, Inc., Houston, TX and Willamette Valley Cancer Center, Eugene, OR
⁶US Oncology Research, Inc., Houston, TX and Florida Cancer Institute, New Port Richey, FL
⁷US Oncology Research, Inc., Houston, TX and Missouri Cancer Associates, Columbia, MO
⁸US Oncology Research, Inc., Houston, TX

Anders Osterborg, MD, PhD¹, Thomas J. Kipps, MD, PhD², Jiri Mayer, MD³, Stephan Stilgenbauer, Prof., Dr., med⁴, Catherine D Williams, MBBS, MRCP, FRCPath^5*, Andrzej Hellmen, MD, PhD^6*, Tadeusz Robak, MD, PhD⁷, Richard R Furman, MD⁸, Peter Hillmen, MBChB, PhD⁹, Marek Trneny, MD, PhD¹⁰, Martin J.S. Dyer, MA, DPhil, FRCP¹¹, Swaminathan Padmanabhan, MD, MBBS¹², Tomas Kozak, MD, PhD^13*, Geoffrey Chan, MD^14*, Randy L Davis, DrPH^15*, Nedjad Losic, MSc^16*, Charlotte A. Russell, MD, DMSC¹⁶, Magdalena Piotrowska, MD^17*, Joris Wilms, MSc., Pharm^16* and William G. Wierda, MD, PhD^18*

¹Deptartment of Hematology, Karolinska Hospital, Stockholm, Sweden
²Moores UCSD Cancer Center, Univ. of California, San Diego, La Jolla, CA
³Hematology/Oncology, University Hospital Brno, Brno, Czech Republic
⁴Internal Medicine III, University of Ulm, Ulm, Germany
⁵Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham, United Kingdom
⁶Department of Hematology, Medical University of Gdansk, Gdansk, Poland
⁷Department of Hematology, Medical University of Lodz, Lodz, Poland
⁸Department of Hematology/Oncology, Weill Cornell Medical College, New York, NY
⁹Department of Haematology, St James' Institute of Oncology, Leeds
¹⁰First Department of Medicine, Charles University General Hosp., Prague, Czech Republic
¹¹MRC Toxicology Unit, Leicester University, Leicester
¹²Cancer Therapy and Research center, UTHSCSA, San Antonio, TX
¹³Department Of Clinical Hematology,, University Hospital Kralovske Vinohrady, Prague, Czech Republic
¹⁴GlaxoSmithKline, Collegeville, PA
¹⁵GlaxoSmithKline, Durham, NC
¹⁶Genmab, Copenhagen, Denmark
¹⁷Department of Hematology, Klinika Hematologii CMUJ, Krakow, Poland
¹⁸MD Anderson Cancer Centre, University of Texas, Houston, TX

Stephan Stilgenbauer¹, Thorsten Zenz^1*, Dirk Winkler^1*, Andreas Bühler^1*, Silja Groner^1*, Raymonde Busch^2*, Manfred Hensel³, Ulrich Dührsen^4*, Juergen Finke⁵, Peter Dreger^6*, Ulrich Jäger^7*, Eva Lengfelder^8*, Lorenz H. Truemper⁹, Ulrike Söling^10*, Rudolf Schlag^11*, Michael Hallek^12* and Hartmut Döhner^1*

¹Internal Medicine III, University of Ulm, Ulm, Germany
²Technical University, Institute for Medical Statistic and Epidemiology, Munich, Germany
³Mannheimer Onkologie Praxis, Mannheim, Germany
⁴University Hospital, Essen, Germany
⁵Dept. of Hematology/Oncology, University Medical Center Freiburg, Germany
⁶Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany
⁷Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
⁸Dept. of Hematology/Oncology, University of Heidelberg, Mannheim, Germany
⁹Dept. of Hem. and Onc., Georg August University, Gottingen, Germany
¹⁰Internistische Gemeinschaftspraxis, Kassel, Germany
¹¹Praxis for Hematology and Oncology, Wurzburg, Germany
¹²Dept. of Internal Med. I, Univeristy of Cologne, Cologne, Germany

Kirsten Fischer, MD^1*, Stephan Stilgenbauer, MD², Carmen D Schweighofer, MD^1*, Raymonde Busch^3*, Jasmin Renschler^1*, Michael Kiehl, MD⁴, Leopold Balleisen, MD^5*, Michael J Eckart, MD^6*, Anna- Maria Fink, MD^1*, Julia Kilp, MD^1*, Matthias Ritgen, MD^7*, Sebastian Böttcher, MD^7*, Michael Kneba, MD, PhD^7*, Hartmut Döhner, MD^2*, Barbara F Eichhorst, MD¹, Michael Hallek, MD¹, Clemens-Martin Wendtner, MD¹ and The German CLL Study Group^8*

¹Department I of Internal Medicine, University of Cologne, Koeln Bonn, Germany
²Department of Internal Medicine III, University Hospital, Ulm, Germany
³Technical University, Institute for Medical Statistic and Epidemiology, Munich, Germany
⁴Department of Internal Medicine, Hospital, Franfurt/Oder, Germany
⁵Department of Internal Medicine, Hospital, Hamm, Germany
⁶ISP, Erlangen, Germany
⁷Department of Internal Medicine II, University Hospital, Kiel, Germany
⁸(GCLLSG)